Vitality International – Pioneering Algorithm Calculates The Number Of Years Individuals Can Expect To Live In Good Health
- Research shows number of years people are spending in ill health is increasing, due to the rising prevalence of chronic diseases, driven by unhealthy lifestyles - Experts call for focus on healthspan, the quality of life, alongside lifespan, the quantity of life, citing significant economic and social benefits - Pioneering...
DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based...
ActionIQ Expands Its CDP Offering into the Healthcare Industry
Completes HIPAA Type I Certification, Is Recertified in SOC 2 Type II Standards NEW YORK, Oct. 12, 2021 /PRNewswire/ -- ActionIQ, the leading Enterprise Customer Data Platform (CDP), today announced that it has expanded its CDP into the healthcare vertical by completing their compliance audit for Health Insurance Portability and Accountability Act...
Integrated Media Technology Limited Enters US$11 Million Conditional Agreement to Acquire an Internet of Medical Things (IoMT) Company
SYDNEY, Oct. 12, 2021 /PRNewswire/ -- Integrated Media Technology Limited (NASDAQ: IMTE) ("IMTE" or the "Company"), announces today the signing of a conditional sale and purchase agreement to acquire 100% equity interest in Magnum International Holdings Limited ("Magnum"), for US$11 million which will be paid by the issuance of 3,630,360 ordinary shares...
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed by Singapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients in Japan, today entered into an exclusive licensing agreement with Albireo Pharma, Inc. (Nasdaq: ALBO) for the development and commercialization of odevixibat in Japan for progressive familial intrahepatic...
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc....
Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare’s Patient Management Platform
SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare, China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strategic partnership to provide Luca's patient management platform of products with online medication refills and delivery...
NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification
Real-time PCR-based human papillomavirus (HPV) detection product is launched. Simultaneous HPV detection and genotyping of 29 HPV types are available. PANGYO, South Korea, Oct. 12, 2021 /PRNewswire/ -- Genematrix (KRX 109820), specialized in real-time PCR based molecular diagnostics, announced that 'NeoPlex™ HPV29 Detection', which can collectively diagnose 29 genotypes of human papillomavirus (HPV; the causative agent...
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production capacity enables Eleva to conduct...
Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021...
HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) will be presented in oral parallel session at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases (AASLD)....
